Article citationsMore>>
Rougier, P, Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P. and Jacques, C. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352, 1407-1412.
has been cited by the following article:
-
TITLE:
Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer
AUTHORS:
Barbara Vandendriessche, Filip Geurs, Ingeborg Hilderson
KEYWORDS:
Colorectal; Elderly; Irinotecan; Second-Line; Unresectable
JOURNAL NAME:
Modern Chemotherapy,
Vol.1 No.2,
October
15,
2012
ABSTRACT: Aims and Background: Irinotecan is a standard option for relapsed/refractory advanced colo- rectal cancer. Combination with raltitrexed and irinotecan at lower than MTD doses should preserve disease stabilisation while decreasing toxicity. Patients and Methods: From January 2004 to April 2009, we analyzed, retrospectively, our data on irinotecan + raltitrexed, fixed doses, as a second-line chemotherapy in elderly pa- tients (>70 years) with advanced colorectal can- cer after failure of oxaliplatin based chemothera- py twenty-three patients were evaluated. Iri- notecan 350 mg + raltitrexed 2.6 mg were given every 3 weeks. Tumo r measurements were ob- tained after every third course of therapy. Toxic- ity was assessed weekly using the National Cancer Institute Common Toxicity Criteria, ver- sion 2. Results: The median number of treatment courses received per patient was 4 (range, 1 - 8). All pa-tients were assessable for toxicity and 21 for response. The most frequently observed severetoxicities were diarrhea (grade 2, 13%) No cases of significant neutropenia occurred. Ob- jective partial responses were observed in 3 pa- tients (13%). An additional 10 patients (43%) had stable disease as their best response. To date, 12 patients have progressed with a median time- to-progression of 4.3 months and a median sur- vival of 8.3 months. Conclusions: A three weekly irinotecan + raltitrexed administration can indu- ce tumor control in elderly patients with advanc- ed colorectalcancer that has progressed during or shortly after oxaliplatin-based chemotherapy. The diarrhea by irinotecan, seems mitigated by coad-ministration of a smaller dose of raltitrexed
Related Articles:
-
H. Abbas, Shimaa Ahmed, Ahmed A. S. Salem, Mohamed Abou Elmagd Salem, Mahmoud Hussin, Wessam A. El Sherief
-
Jai Dev Chandel, Nand Lal Singh
-
Wei Li, Zhaojun Qian, Huiyu Li
-
Abdelhamid M. Fouad, Magdy M. Saber, Yahia M. Ismail, Yasser A. Sallam, Tarek M. Shouman, Reham A. A. Elshimy, Ahmed Abo Gabal
-
Mirwais Rashid